home / press / releases

Menu
  • Search all tables

releases: https://doggett.house.gov/media-center/press-releases/source-drug-prices-spike-and-action-called

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://doggett.house.gov/media-center/press-releases/source-drug-prices-spike-and-action-called The Source: Drug Prices Spike and Action is Called For 2015-12-16 2015 2015-12 Democrat House TX Lloyd Doggett D000399 doggett.house.gov     legacy by: Paul Flahive The big story, the one that made news directors perk up their ears, made congressmen call hearings, and made jaws drop across the country was the story about a 62 year-old drug - a senior citizen of a drug - called Daraprim that overnight went from $13.50 a tablet to $750 a tablet. A 5000% increase for no other reason than a company called Turing Pharmaceuticals bought the drug and raised the price because it could. The drug is used to treat malaria, HIV, and other infections. Overnight the story of the cost surges in drugs was no longer about new drugs, but about all drugs, even old ones. A long known problem with drug pricing practices had coalesced around a single action. The murky world of drug pricing lacks transparency and according to Congressman Lloyd Doggettit lacks many elements of what make up a free market. "The problem is we don't have a free market, we have a monopoly market," says Doggett. "What we need is more competition and more information for consumers." The congressman has launched a task force to investigate the high prices, something that the U.S. Senate has also done. These kinds of investigations can often shed some light how decisions are made and how an industry is run. Congressional investigations and hearings are nothing new to the pharmaceuticalindustry. In fact, 50 years ago a Kentucky Democrat named Estes Kefauverheld several hearings that had incredible impact says Medical historian Jeremy Greene "It was really an amazing and eye-opening investigation. He used the power of the subpoena to bring executivesof pharmaceutical companies as well as the head of the AMA and FDA and the U.S. patent and trademark office into the congressional hearings," says Greene. "Previously obscure pricing and marketing practicesof the industry became visible to the American people to then act upon" What can we do today to reign in drug costs? Guests: Rep. Lloyd Doggett, U.S. Congressman from Texas' 35th district Leigh Purvis, Director of Health Services Research at AARP Katie Verb, Associate Director of Policy & Government Relations for the Hemophilia Federation of America Dr. Jeremy Greene, Associate Professor of Medicine and the History of Medicine Stephen W. Schondelmeyer, Head of the Department of Pharmaceutical Care and Health Systems at the University of Minnesota. 1 2026-03-30T12:14:52Z 2026-03-30T12:14:52Z
Powered by Datasette · Queries took 1.348ms · Data license: MIT · Data source: dwillis/congress-press